SG11201502949QA - Bremelanotide therapy for female sexual dysfunction - Google Patents

Bremelanotide therapy for female sexual dysfunction

Info

Publication number
SG11201502949QA
SG11201502949QA SG11201502949QA SG11201502949QA SG11201502949QA SG 11201502949Q A SG11201502949Q A SG 11201502949QA SG 11201502949Q A SG11201502949Q A SG 11201502949QA SG 11201502949Q A SG11201502949Q A SG 11201502949QA SG 11201502949Q A SG11201502949Q A SG 11201502949QA
Authority
SG
Singapore
Prior art keywords
bremelanotide
therapy
sexual dysfunction
female sexual
female
Prior art date
Application number
SG11201502949QA
Other languages
English (en)
Inventor
Carl Spana
Robert Jordan
Jeffrey D Edelson
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201502949Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of SG11201502949QA publication Critical patent/SG11201502949QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
SG11201502949QA 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction SG11201502949QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (fr) 2012-11-05 2013-11-05 Utilisations de brémélanotide dans une thérapie de dysfonctionnement sexuel féminin

Publications (1)

Publication Number Publication Date
SG11201502949QA true SG11201502949QA (en) 2015-06-29

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502949QA SG11201502949QA (en) 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction

Country Status (24)

Country Link
US (6) US9352013B2 (fr)
EP (1) EP2916856B2 (fr)
JP (1) JP6567971B2 (fr)
KR (1) KR102253526B1 (fr)
CN (2) CN104755094A (fr)
AU (1) AU2013337341B2 (fr)
BR (1) BR112015009936A8 (fr)
CA (1) CA2890081A1 (fr)
DK (1) DK2916856T4 (fr)
EA (1) EA032959B9 (fr)
ES (1) ES2701444T5 (fr)
FI (1) FI2916856T4 (fr)
GE (1) GEP20196947B (fr)
HK (1) HK1211227A1 (fr)
IL (1) IL238276B (fr)
MX (1) MX362610B (fr)
MY (1) MY179755A (fr)
NZ (1) NZ707246A (fr)
PH (1) PH12015500915A1 (fr)
PL (1) PL2916856T5 (fr)
SG (1) SG11201502949QA (fr)
UA (1) UA118656C2 (fr)
WO (1) WO2014071339A2 (fr)
ZA (1) ZA201503128B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60112440T2 (de) * 2000-05-31 2006-04-20 Novo Nordisk A/S Wegwerfbare zweispitzige injektionsnadel
JP2004534851A (ja) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
CN101484198A (zh) * 2004-12-09 2009-07-15 韦斯特制药服务公司 尾部装有固定针的注射器和具有该注射器的自动注射装置
WO2009120656A1 (fr) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Préparation pharmaceutique pour indications oculaires
WO2009152079A1 (fr) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Peptides spécifiques du récepteur de mélanocortine pour le traitement d'un dysfonctionnement sexuel
RU2548753C2 (ru) * 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
KR101850687B1 (ko) * 2010-04-21 2018-04-20 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스

Also Published As

Publication number Publication date
WO2014071339A3 (fr) 2014-06-12
US20150231196A1 (en) 2015-08-20
MY179755A (en) 2020-11-12
IL238276B (en) 2020-04-30
DK2916856T3 (en) 2019-01-14
KR102253526B1 (ko) 2021-05-18
PH12015500915B1 (en) 2015-06-29
BR112015009936A2 (pt) 2017-07-11
AU2013337341A1 (en) 2015-05-07
MX362610B (es) 2019-01-28
EP2916856A4 (fr) 2016-06-22
KR20150081345A (ko) 2015-07-13
CN117860866A (zh) 2024-04-12
EA032959B9 (ru) 2019-11-27
GEP20196947B (en) 2019-02-11
AU2013337341B2 (en) 2018-02-22
US20140378392A1 (en) 2014-12-25
PL2916856T3 (pl) 2019-02-28
US20220362328A1 (en) 2022-11-17
EP2916856A2 (fr) 2015-09-16
IL238276A0 (en) 2015-06-30
NZ707246A (en) 2019-03-29
US20180085425A1 (en) 2018-03-29
PL2916856T5 (pl) 2024-01-29
US20190216888A1 (en) 2019-07-18
MX2015005486A (es) 2015-11-13
JP2016503406A (ja) 2016-02-04
ES2701444T5 (es) 2024-05-21
US20210060120A1 (en) 2021-03-04
DK2916856T4 (da) 2024-01-22
EA201590760A1 (ru) 2015-10-30
US9352013B2 (en) 2016-05-31
ES2701444T3 (es) 2019-02-22
FI2916856T4 (fi) 2024-01-15
JP6567971B2 (ja) 2019-08-28
CN104755094A (zh) 2015-07-01
ZA201503128B (en) 2016-11-30
HK1211227A1 (en) 2016-05-20
UA118656C2 (uk) 2019-02-25
EA032959B1 (ru) 2019-08-30
PH12015500915A1 (en) 2015-06-29
CA2890081A1 (fr) 2014-05-08
BR112015009936A8 (pt) 2019-09-17
WO2014071339A2 (fr) 2014-05-08
US10286034B2 (en) 2019-05-14
US9700592B2 (en) 2017-07-11
EP2916856B1 (fr) 2018-09-19
EP2916856B2 (fr) 2023-10-18

Similar Documents

Publication Publication Date Title
LT2726048T (lt) Seksualinės stimuliacijos įrenginys
GB2512765B (en) Devices and methods for promoting female sexual wellness
PL2964315T3 (pl) Układ do leczenia dysfunkcji neuromotorycznej
HK1221424A1 (zh) 治療癌症的藥物組合
EP2906208A4 (fr) Traitement thérapeutique
GB201119608D0 (en) Stimulation apparatus
GB201006495D0 (en) Sexual stimulator
HK1217445A1 (zh) 瞼板腺功能障礙的治療劑
EP2666454A4 (fr) Dispositif d'aide à la masturbation masculine
EP2777680A4 (fr) Dispositif pour la stimulation sexuelle féminine
HK1204325A1 (en) Phragamalin limonoids for the treatment of sexual dysfunction phragmalin
EP2777679A4 (fr) Dispositif pour la stimulation sexuelle masculine
EP2910234A4 (fr) Appareil de massage hydraulique
ZA201308176B (en) Therapeutic treatment
HK1211227A1 (en) Bremelanotide therapy for female sexual dysfunction
HK1209342A1 (en) A3 Adenosine Receptor Ligands For Use In Treatment Of A Sexual Dysfunction A3
HUE050066T2 (hu) Meibom-mirigy rendellenességek kezelésére szolgáló gyógyszerészeti szer
GB201317518D0 (en) Versatile sexual stimulation devices
TWM475277U (en) Sexual massage cup
SG2013090550A (en) Muscle stimulation system
GB201217173D0 (en) Therapeutic method
GB201119736D0 (en) Muscle stimulation